GHO capital launches EU’s largest fund ever for life sciences
GHO Capital raises 975m in largest ever European private equity healthcare fund.
Zelluna Immunotherapy and Glycostem Therapeutics in licence deal
Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.
Novo secures Dicernas RNAi liver assets
Danish Novo Nordisk A/S has secured access to Dicerna Incs GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.
EU with poor success in fighting superbugs
The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
Cellectis presents way to safer CAR-Ts
Researchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.
Update: BIO-Europe growing further
Europe’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.
Magenta Therapeutics exercises ATAC licence option
Magenta Therapeutics has exercised the option to licence Heidelberg Pharma AGs anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC).
SciRhom targets autoimmunity switch
Autoimmunity specialist SciRhom GmbH has kicked of a first-in-class antibody development programme targeting iRhom2.
AMR: ENABLE selects Mutabilis candidate
A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE programme of the Innovative Medicines Initiative (IMI).
NSCLC: Bemcentinib + anti-PD1 triple PFS
Bergen Bio ASAs Axl kinase blocker bemcentinib in combination with MSDs pembrolizumab has met the primary endpoint in a Phase II study in patients with non small cell lung cancer (NSCLC).